Sonobird: a pivotal trial in recurrent glioblastoma
SONOBIRD is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients undergoing planned resection for first recurrence of glioblastoma.
What is the Sonobird trial?
Sonobird is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients undergoing planned resection for first recurrence of glioblastoma.
Discover the Sonobird clinical trial
Who can participate?
This trial is open to adult patients at first recurrence of glioblastoma after initial therapy, to whom doctors recommend a new partial or total tumor resection and chemotherapy.
Check the eligibility criteria for this clinical trial
Contacting a recruitment center
The Sonobird trial is currently recruiting patients in Europe and the United States of America. Find below the sites currently participating in the trial.
About SonoCloud
For a better understanding of how our medical device works, please visit the page dedicated to the ultrasound technology used in “SonoCloud”. This device temporarily opens the blood-brain barrier to maximize the passage of chemotherapy into the brain, thereby potentially enhancing its effect against glioblastoma.
To meet the team behind the development of the SonoCloud, please consult the “About Us” page. ». You’ll discover our history, our commitment and our achievements.